Cargando…

MTOR inhibitor-based combination therapies for pancreatic cancer

BACKGROUND: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs furt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan, Zonera, Schneeweis, Christian, Wirth, Matthias, Veltkamp, Christian, Dantes, Zahra, Feuerecker, Benedikt, Ceyhan, Güralp O, Knauer, Shirley K, Weichert, Wilko, Schmid, Roland M, Stauber, Roland, Arlt, Alexander, Krämer, Oliver H, Rad, Roland, Reichert, Maximilian, Saur, Dieter, Schneider, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808033/ https://www.ncbi.nlm.nih.gov/pubmed/29384525 http://dx.doi.org/10.1038/bjc.2017.421

Ejemplares similares

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
por: Schneeweis, Christian, et al.
Publicado: (2022)

Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC
por: Lankes, Katharina, et al.
Publicado: (2020)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
por: Diersch, Sandra, et al.
Publicado: (2015)

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
por: Biederstädt, Alexander, et al.
Publicado: (2020)

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
por: Schneeweis, Christian, et al.
Publicado: (2022)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
por: Zuo, M, et al.
Publicado: (2015)

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
por: Jimeno, A, et al.
Publicado: (2007)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
por: Makhov, P, et al.
Publicado: (2014)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
por: Liu, Weiwei, et al.
Publicado: (2017)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells
por: Sudhagar, S, et al.
Publicado: (2011)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
por: Orben, Felix, et al.
Publicado: (2022)

CXCR7-mediated progression of osteosarcoma in the lungs
por: Goguet-Surmenian, E, et al.
Publicado: (2013)

CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver
por: Guillemot, E, et al.
Publicado: (2012)

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
por: Wirth, Matthias, et al.
Publicado: (2014)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

The SUMO pathway in pancreatic cancer: insights and inhibition
por: Schneeweis, Christian, et al.
Publicado: (2020)

Metabolic Response of Pancreatic Carcinoma Cells under Treatment with Dichloroacetate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy
por: Fankhauser, Christian Daniel, et al.
Publicado: (2018)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kkpad0e5m9fin8aq7ro26e7fon